Journal of Clinical Case reports and Images

 

 

Special Issue On:- Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

 

Special Issue By:- Dr. Anıl Tombak

This special issue calls for original papers with important and novel contributions related to:- 

“Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma”

 

Topics of interests include:

• chronic lymphocytic leukemia

• small lymphocytic lymphoma

• chemotherapy

• antibodies

• biology

• small molecules

• molecular pathogenesis

 

Metrics:

Acceptance period: 14 days from the submitted date People involved: Dr. Anıl Tombak  - Editor

Welcomes submissions to the thematic concept on 'Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma'. 

 

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a mature B cell neoplasm characterized by a progressive accumulation of monoclonal B lymphocytes. CLL/SLL is the most common leukemia in adults in Western countries, accounting for approximately 25 to 30 % of all leukemias. CLL/SLL is considered to be mainly a disease of older adults, with a median age at diagnosis of approximately 70 years. However, the disease can be diagnosed in younger individuals, but its incidence increases rapidly with increasing age. In recent years, several discoveries have increased our understanding of the genetic and molecular mechanisms contributing to the onset and progression of chronic lymphocytic leukemia (CLL). Recently published data have indicated important pathogenetic steps involved in the survival and progression of CLL cells, and identified markers that are critical for better stratification of the patients. The discovery of intracellular signalling pathways, the understanding of BCR signalling has opened new horizons. With these discoveries, the success of treatment even in the elderly patients has increased.

 

In this special issue, it is planned to be mentioned about the epidemiology, pathogenesis and genetic features, clinical features, diagnosis, staging and prognosis, complications, and treatment of CLL/SLL. In the treatment arm, instead of current chemotherapy strategies, new agents including obinutuzumab, ofatumumab, ibrutinib, idelalisib and venetoclax will be discussed in newly diagnosed and relapsed/refractory patients. Allogeneic bone marrow transplantation is the only curative therapy today and it is also planned to be discussed in this special issue.

 

Submission Instructions: All submissions will undergo peer review and accepted articles will be published in the Journal of Clinical Case reports and Images (ISSN: 2641-5518).

 

Reviews which include the comparative view, Original research papers as well as short communications and letters on new developments and applications are welcome and are to be written in Standard English. Formatting of the manuscript with headings and Subheadings is necessary and views are to be presented clearly. New approaches are mainly in interest.

 

To cover the costs of publication, an Article Processing Charge is essential and the charge levied for each article of any type upon acceptance is $900 USD.